Related Experiment Videos
[Cytoplasmic immunoglobulins in chronic B-lymphoid leukemia]
J F Filippi1, C Nicolino-Brunet, N Tubiana
1Laboratoire d'Hématologie Biologique, Faculté de Médecine et de Pharmacie, Marseille, France.
Pathologie-Biologie
|January 1, 1991
Summary
Detecting both surface and cytoplasmic immunoglobulins in chronic lymphocytic leukemia B-cells significantly improves monoclonality assessment. This combined approach is more effective than surface immunoglobulin analysis alone for diagnosing B-cell chronic lymphocytic leukemia.
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Assessing monoclonality is crucial for CLL diagnosis and management.
- Surface immunoglobulin (Smlg) and cytoplasmic immunoglobulins (Clg) are key B-cell markers.
Purpose:
- To evaluate the diagnostic utility of combined surface and cytoplasmic immunoglobulin detection in B-cell chronic lymphocytic leukemia (B-CLL).
- To assess the expression of CD10 and other membrane markers in B-CLL.
- To explore correlations between immunologic markers and clinical staging in B-CLL.
Summary:
- A study of 60 B-CLL cases found that combined Smlg and Clg determinations identified monoclonality in 65% of cases, compared to 38% with Smlg alone.
- Monoclonal antibody analysis revealed CD10 positivity in 36% of patients.
- No significant correlations were observed between immunologic markers and clinical stage.
Impact:
- Combined immunoglobulin analysis enhances the diagnostic accuracy for B-cell chronic lymphocytic leukemia.
- This improved diagnostic approach aids in better patient stratification and treatment planning.
- Understanding B-cell marker expression provides insights into CLL pathogenesis and potential therapeutic targets.